News

The panel can be analyzed on the full line of nCounter Analysis Systems, including the new nCounter SPRINT™ Profiler, utilizing breakthrough technology, which simultaneously measures both RNA and

Alligent is a leading Medical Affairs agency that develops and delivers strategically-focused, integrated and aligned medical communications solutions to the biopharma industry. The deal was supported by the

The company will undertake the open-label Phase 2 trial in collaboration with MD Anderson Cancer Center in Houston. About 25 patients are expected to be enrolled in the

BL-5010 is a novel product for the non-surgical removal of benign skin lesions. It offers an alternative to painful, invasive and expensive removal treatments including cryotherapy, laser treatment

Bioceros is a privately-held, Netherlands-based biopharmaceutical R&D company focused on the development of mAbs and generation of GMP-ready cell lines. Over the past decade, Bioceros has developed numerous

The trial will evaluate the safety of Eliquis in patients with nonvalvular atrial fibrillation (NVAF) with a recent acute coronary syndrome (ACS) or undergoing percutaneous coronary intervention (PCI).

The randomized, double-blinded, dose-ranging, placebo-controlled Phase 2 trial will evaluate the safety and efficacy of a single, bilateral application of RT001 topical gel for the treatment of primary

US-based New Science Ventures led the financing round, which also included Belgian investors VIVES Louvain Technology Fund, NivelInvest, Fund+, Integrale, SRIW, SFPI-FPIM, Epimède and other individual participants. The

The company’s EySite-NanoM is a sustained-release delivery system designed to offer continuous release of its therapeutic anti-glaucoma agent for preventing the peak and trough drug levels that take